Market capitalization | $910.04m |
Enterprise Value | $637.75m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 3.50 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-184.29m |
Free Cash Flow (TTM) Free Cash Flow | $-155.96m |
Cash position | $273.14m |
As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.
11 Analysts have issued a Pharvaris NV forecast:
11 Analysts have issued a Pharvaris NV forecast:
Mar '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -184 -184 |
53%
53%
|
EBIT (Operating Income) EBIT | -184 -184 |
53%
53%
|
Net Profit | -176 -176 |
44%
44%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Pharvaris NV is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Hans G. C. P. Schikan and Anne Lesage on September 30, 2015 and is headquartered in Leiden, Netherlands.
Head office | Netherlands |
CEO | Berndt Modig |
Employees | 83 |
Founded | 2015 |
Website | pharvaris.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.